Panitumumab 20mg/ml solution injection in 5ml/10ml/20ml in single use vials,
|20mg/ml inj.||0.00||in 5ml/10ml/20ml in single use vials|
List of Related Indications:
- Colorectal carcinoma
List Of Drugs:
- Panitumumab - @ - Monoclonal Antibodies - Antineoplastic Agents
Indication Type Description:
Dosages/ Overdosage Etc
Pregnancy and lactation
Drug interactions -summary
Irinotecan - frequency and severity of diarrhea increased when panitumumab s given
concomittamtly with irinotecan. Avoid co-administration
Common adverse reactions-
abdominal pain, diarrhea,( including diarrhea resulting in dehydration) fatigue,
hypomagnesiumia, paronychia, nausea, skin and rash
Serious adverse reactions-
abdominal pain, constipation, infusion reactions, hypomagnesiumnia, pulmonary fibrosis,
nausea, severe dermatolgical toxicity, coplicated by infectious sequelae and septic death
Adverse reactions requiring discontinuation were infusion reactions, paronychia,
pulmonary fibrosis and severe skin toxicity
Dermatologic - all skin /integument toxicity 85% hair 8% growth of eye lashes 5%
nail 25% other nail disorders 8% paronnychia 23% skin 85%
acne 12% acneform dermitis 53% dry skin 8% eryhthema 60%
pruritus 52% rash 20% skin exfoliation 23% skin fissures 18%
GI - abdominal pain 22% constipation 20% diarrhea 20% nausea 21%
Metabolic /nutritional - hypomagnesiumia 35% periheral edema 10%
Respiratory - cough 12%
Special senses - eye related toxicites 12%
Miscellaneous - fatigue 23% general deterioration 10%
Infusion reactions- depending on the severity and/or persistence of the reaction, permanently discontinue pantitumumab
Pulmonary fibrosis - permanently discontinue panitumumab therapy in patients developing interstitial lung infiltration or pneumonitis
Electrolyte depletion- periodically monitor patients electrolytes during and for 8 weeks after the completion of panitumumab therapy
Photosensitivity -It is recommended that patients wear sunscreen and hats and limit sun exposure while receiving the drug because sunlight can exacerbate skin reactions tat may occur.
Pregnancy- If panitumumab is used during pregnancy or if the patient becomes pregnant while receiving the drug, explain to her the potential risk to the loss of pregnancy or the potential hazards to the fetus,
Lactation- advice women to discontinue breast-feeding during treatment with the drug and for 2 months after the last dose of panitumumab
Children- Safety and efficacy has not been established in children.
Monitoring- monitor vital signs, heart rate, blood pressure, respiratory rate, temperature every 15 to 30 minutes during infusion and for 1 hourafterwards.
Monitor patients for inflammatory or infectious sequelae in patients with severe dermatological toxicites.
Monitor patients during administration of infusion
Dosages/ Overdosage Etc:
6mg/kg adninistered 60 minutes as an intrevenous IV infusion through a peripheral
linevindwelling catheter every 14 days . Dose higher than 1000mg should be over 90 minutes
Reduce the infusion 50% in patients experiencing a mild to moderate ( grade 1 to 2 ) reaction for the duration of that infusion
Immediately and permanently discontinue in patients experiencing severe ( grade 3 or 4 ) infusion reactions
1. Inform patients of the possible adverse reactions of panitumumab including dermatological toxicity , infusion reactions, pulmonary fibrosis, and potential embryofetal lethality .
2. Instruct patients to report skin and ocular changes and dyspnea to their doctor.
3. Instruct patients that periodic monitoring of electrolye levels are required
4. In women of child bearing age, appropiate contraceptive methods must be used during
treatment with penitumumab and for 6 months following the last dose of panitumumab
5. Advice women to discontinue breast feeding during treatmentand for 2 months after the
last dose of the drug.
5. It is recommended that patients wear sunscreen and hats and limit sun exposure
while receiving the drug because sunlight can exacerbate skin reactions tat may occur.
Pregnancy and lactation:
If panitumumab is used during pregnancy or if the patient becomes pregnant while
receiving the drug, explain to her the potential risk to the loss of pregnancy or the potential
hazards to the fetus,
Advice women to discontinue breast-feeding during treatment with the drug and for
2 months after the last dose of panitumumab
Safety and efficacy has not been established in children.